SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Minos who wrote (9269)5/10/1998 1:08:00 PM
From: Jenna  Read Replies (2) of 120523
 
XOMA ..very nice chart. Stock was recently upgraded. All my indicators are bullish on XOMA. Relative Strength is neutral, Volume Indicators point to XOMA being under ACCUMULATION. 10, 20, 50 day moving averages are rising, Stock was also recently upgraded. So technically, XOMA looks fine. Money Flow Indicator all positive. (MACD) indicates a BULLISH trend.

VTEL Corporation is the world's largest developer and manufacturer of Digital Visual Communications(SM) systems. VTEL's innovative products provide superior video, data and voice quality, are simple-to-use, IP addressable, and because they aremicrocomputer-based, highly scaleable and easily upgradeable. Headquartered in Austin, Texas, the company distributes products through value-added resellers and partners in 55 countries. VTEL is committed to expanding its leadership position by providing the world's most innovative video networking, custom room solutions, and project/facility management. VTEL's Digital Visual Communications systems are deployed in the mostadvanced corporations, healthcare facilities, educational institutions and government operations around the globe. Consensus Estimate for Current Quarter is 2 cents up from 1 cent last quarter. Rel Performance/strength in the last week has been excellent. Earnings acceleration is strong. ERG has improved very nicely in the last week. EPS is going to improve next fiscal year. Right now it's sector is in favor which is good.

Here is an interesting article I saw on Friday night:
Friday May 8, 7:47 pm Eastern Time

Company Press Release

Boston Life Sciences, Guilford and OSI Pharmaceuticals To
Present At Beltway Biotech Investors Forum June 6

BETHESDA, Md.--(BUSINESS WIRE)--May 8, 1998--Boston Life Sciences (NASDAQ:BLSI -
news), OSI Pharmaceuticals (NASDAQ:OSIP - news) and Guilford Pharmaceuticals
(NASDAQ:GLFD - news) have committed to be presenting companies at the First Annual Informed
Investors Beltway Biotechnology Stocks Forum Saturday June 6 at the Hyatt Regency Bethesda.

The Forum runs from 9 a.m.-12:30 p.m. and is preceded by a breakfast buffet at 8 a.m.

''This week's volatility in shares of Entremed, Inc. (NASDAQ:ENMD - news) brings into focus the
need for investors to have perspective about biotech investing,'' said Tim Quast, Chief Operating
Officer of Informed Investors, Inc. of Sacramento, organizer of the event.

''While no doubt biotechnology is an area of exciting promise for educated investors, it is important to
understand the psychology and realities of biotech investing. Investors must be patient and watch their
investments over the long term since many biotech companies are still in their developmental stages.
Along with opportunities for high returns, there is a lot of risk, too.''

In addition to Entremed, heightened trading activity has spilled over into other biopharma stocks
including Immunogen (NASDAQ:IMGN - news), Repligen (NASDAQ:RGEN - news), Sugen
(NASDAQ:SUGN - news), Imclone Systems (NASDAQ:IMCL - news), Magainin Pharmaceuticals
(NASDAQ:MAGN - news), Genderm Corp. (NASDAQ:GEND - news), Techniclone
(NASDAQ:TCLN - news), Bradley Pharmaceuticals (NASDAQ:BPRX - news), Organogenesis
(AMEX:ORG - news) and U.S. Bioscience (AMEX:USB - news).

The Forum features a keynote address by Kris Jenner, Healthcare Analyst at T. Rowe Price
Associates, the Baltimore-based mutual fund family. Jenner covers biotechnology and pharmaceutical
companies. His talk will give attendees perspectives from both the science and investing disciplines.

A highlight will be analyst-style presentations from top executives from up to six biotechnology
companies. Executives give 20-25 minute presentations followed by Q&A. This format is common at
investment banking conferences that are closed to individual investors. The other three presenting
companies will be announced shortly.

The cost to attend, which includes a full breakfast buffet served prior to the Forum, is $25 prepaid, $40
at the door. Call Informed Investors at 800/992-4683 to register. Audio tapes are available for investors
unable to attend. Tapes are $45 plus $3.95 S/H which includes all company presentations plus keynote
speakers. Individual company tapes are $18. Access Informed Investors' website at
informedinvestors.com for more information and updates.


Here is an interesting article I saw on Friday night:
Friday May 8, 7:47 pm Eastern Time

Company Press Release

Boston Life Sciences, Guilford and OSI Pharmaceuticals To
Present At Beltway Biotech Investors Forum June 6

BETHESDA, Md.--(BUSINESS WIRE)--May 8, 1998--Boston Life Sciences (NASDAQ:BLSI -
news), OSI Pharmaceuticals (NASDAQ:OSIP - news) and Guilford Pharmaceuticals
(NASDAQ:GLFD - news) have committed to be presenting companies at the First Annual Informed
Investors Beltway Biotechnology Stocks Forum Saturday June 6 at the Hyatt Regency Bethesda.

The Forum runs from 9 a.m.-12:30 p.m. and is preceded by a breakfast buffet at 8 a.m.

''This week's volatility in shares of Entremed, Inc. (NASDAQ:ENMD - news) brings into focus the
need for investors to have perspective about biotech investing,'' said Tim Quast, Chief Operating
Officer of Informed Investors, Inc. of Sacramento, organizer of the event.

''While no doubt biotechnology is an area of exciting promise for educated investors, it is important to
understand the psychology and realities of biotech investing. Investors must be patient and watch their
investments over the long term since many biotech companies are still in their developmental stages.
Along with opportunities for high returns, there is a lot of risk, too.''

In addition to Entremed, heightened trading activity has spilled over into other biopharma stocks
including Immunogen (NASDAQ:IMGN - news), Repligen (NASDAQ:RGEN - news), Sugen
(NASDAQ:SUGN - news), Imclone Systems (NASDAQ:IMCL - news), Magainin Pharmaceuticals
(NASDAQ:MAGN - news), Genderm Corp. (NASDAQ:GEND - news), Techniclone
(NASDAQ:TCLN - news), Bradley Pharmaceuticals (NASDAQ:BPRX - news), Organogenesis
(AMEX:ORG - news) and U.S. Bioscience (AMEX:USB - news).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext